Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18898666 | 0.76 | SMN1; SMN2 (0.37) | NPC1SCN4ARAB9ASMN1; SMN2NOS1 | |
| SCHEMBL6258086 | 0.74 | NOS1 (0.52) | NPC1SCN4ARAB9ASMN1; SMN2NOS1 | |
| SCHEMBL10986635 | 0.74 | FBP1 (0.37) | NPC1SCN4ARAB9ASMN1; SMN2NOS1 | |
| SCHEMBL20346770 | 0.73 | SMN1; SMN2 (0.35) | NPC1SCN4ARAB9ASMN1; SMN2NOS1 | |
| SCHEMBL21737735 | 0.73 | — | — | |
| SCHEMBL14803850 | 0.73 | SMN1; SMN2 (0.35) | NPC1SCN4ARAB9ASMN1; SMN2NOS1 | |
| SCHEMBL404505 | 0.73 | MEN1 (0.37) | NPC1SCN4ARAB9ASMN1; SMN2NOS1 | |
| SCHEMBL28216048 | 0.70 | CYP1A2 (0.38) | NPC1SCN4ARAB9ASMN1; SMN2NOS1 | |
| SCHEMBL19059552 | 0.70 | — | — | |
| SCHEMBL27459038 | 0.68 | FBP1 (0.40) | NPC1SCN4ARAB9ASMN1; SMN2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973051-B2 | Aminothiazoles as FBPase inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | disclosed |
| CN-101878211-A | Aminothiazole derivs | HOFFMANN LA ROCHE | 2010-11-03 | — | — | CN | disclosed |
| EP-2227468-A1 | AMINOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| WO-2009068467-A1 | AMINOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | FBP1, SLC5A1, DPP4 | NPC1 2662/4885SCN4A 3216/4885RAB9A 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.